Molecular characteristics of human platelet monoamine oxidase

  • Christopher J. Fowler
  • Åsa Wiberg
Article

Summary

The monoamine oxidase B (MAO-B) selective inhibitor J-508 (N-methyl-N-propargyl-(1-indanyl)-ammonium chloride) appears to interact with MAO-B in a manner consistent with a ‘suicide’ reaction. Because of this property, J-508 could be used, under the appropriate conditions, to ‘titrate’ the concentration of MAO-B active centres in the human platelet, although some non-specific binding of this compound to sites other than the active centre of this enzyme form was found, thus limiting the accuracy of the titration method. The molecular characteristics of human platelet MAO-B (Km, Vmax, approximate enzyme concentrations and molecular turnover numbers) towards three of its monoamine substrates have been estimated. The natural variation of platelet MAO-B activity from individual to individual is due to a variation in the Vmax without a variation in the Km towards benzylamine as substrate, and is based, at least in part, upon a variation in the concentration of this enzyme form.

Key words

Monoamine oxidase Enzyme titration Human platelets 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abeles, R. H., Maycock, A. L.: Suicide enzyme inactivators. Acc. Chem. Res. 9, 313–319 (1976)Google Scholar
  2. Browne, B. J., Fowler, C. J., Callingham, B. A.: The effects of homogenisation of rat liver in different buffer solutions on the yield and kinetic properties of monoamine oxidase. J. Pharm. Pharmacol. 30, 573–575 (1978)Google Scholar
  3. Buchsbaum, M. S., Coursey, R. D., Murphy, D. L.: The biochemical high-risk paradigm: behavioural and familial correlates of low platelet monoamine oxidase activity. Science 194, 339–341 (1976)Google Scholar
  4. Callingham, B. A., Laverty, R.: Studies on the nature of the increasing monoamine oxidase activity in the rat heart after adrenalectomy. J. Pharm. Pharmacol. 25, 940–947 (1973)Google Scholar
  5. Donnelly, C. H., Murphy, D. L.: Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26, 853–858 (1977)Google Scholar
  6. Edwards, D. J., Burns, M. O.: Effects of tricyclic antidepressants upon human platelet monoamine oxidase. Life Sci. 15, 2045–2058 (1974)Google Scholar
  7. Edwards, D. J., Chang, S.-S.: Evidence for interacting catalytic sites of human platelet monoamine oxidase. Biochem. Biophys. Res. Commun. 65, 1018–1025 (1975)Google Scholar
  8. Egashira, T., Ekstedt, B., Kinemuchi, H., Wiberg, Å, Oreland, L.: Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat. Med. Biol. 54, 272–277 (1976)Google Scholar
  9. Fowler, C. J., Callingham, B. A.: The inhibition by clorgyline of 5-hydroxytryptamine deamination in the rat liver. J. Pharm. Pharmacol. 30, 304–309 (1978)Google Scholar
  10. Fowler, C. J., Callingham, B. A.: The inhibition of rat heart type A monoamine oxidase by clorgyline as a method for the estimation of enzyme active centres. Mol. Pharmacol. 16, 546–555 (1979)Google Scholar
  11. Fowler, C. J., Oreland, L.: Substrate-selective interaction between monoamine oxidase and oxygen. In: Monoamine oxidase: structure, function and altered functions (T. P. Singer, R. W. Von Korff and D. L. Murphy, eds.), pp. 145–151. New York: Academic Press 1979)Google Scholar
  12. Fowler, C. J., Ekstedt, B., Egashira, T., Kinemuchi, H., Oreland, L.: The interaction between human platelet monoamine oxidase, its monoamine substrates and oxygen. Biochem. Pharmacol. 28, 3063–3068 (1979)Google Scholar
  13. Fowler, C. J., Callingham, B. A., O'Connor, M. D. L., Matthews, E. K.: The effect of sonication upon monoamine oxidase-A and-B in the rat liver. Biochem. Pharmacol. 29, 1185–1188 (1980a)Google Scholar
  14. Fowler, C. J., Oreland, L., Marcusson, J., Winblad, B.: Titration of human brain monoamine oxidase-A and-B by clorgyline and l-deprenil. Naunyn-Schmiedeberg's Arch. Pharmacol. 311, 263–272 (1980b)Google Scholar
  15. Houslay, M. D., Tipton, K. F.: The reaction pathway of membrane-bound rat liver mitochondrial monoamine oxidase. Biochem. J. 135, 735–750 (1973)Google Scholar
  16. Johnston, J. P.: Some observations on a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968)Google Scholar
  17. Knoll, J., Magyar, K.: Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5, 393–408 (1972)Google Scholar
  18. Knoll, J., Eczery, Z., Magyar, K., Satory, E.: Novel (−)deprenylderived selective inhibitors of B-type monoamine oxidase. Biochem. Pharmacol. 27, 1739–1747 (1978)Google Scholar
  19. Major, L. F., Murphy, D. L.: Platelet and plasma amine oxidase activity in alcoholic individuals. Br. J. Psychiat. 132, 548–554 (1978)Google Scholar
  20. Markwell, M. A. K., Haas, S. M., Bieber, L. L., Tolbert, N. E.: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87, 206–210 (1978)Google Scholar
  21. Murphy, D. L.: Clinical, genetic, hormonal and drug influences on the activity of human platelet monoamine oxidase. In: Monoamine oxidase and its inhibition. Ciba Foundation Symposium 39 (G. E. W. Wolstenholme and J. Knight, eds.), pp. 341–351. Amsterdam: Elsevier, Exerpta Medica, North Holland 1976Google Scholar
  22. Nies, A., Robinson, D. S., Lamborn, K. R., Lampert, R. P.: Genetic control of platelet and plasma monoamine oxidase activity. Arch. Gen. Psychiat. 28, 834–838 (1973)Google Scholar
  23. Oreland, L.: The activity of human brain and thrombocyte monoamine oxidase (MAO) in relation to various psychiatric disorders. 1) MAO activity in some disease states. In: Monoamine oxidase; structure, function and altered functions (T. P. Singer, R. W. Von Korff and D. L. Murphy, eds.), pp. 379–387. New York: Academic Press 1979Google Scholar
  24. Oreland, L.: Monoamine oxidase activity and affective illness. Acta Psychiat. Scand. 61, Suppl. 280, 41–46 (1980)Google Scholar
  25. Perris, C., Jacobsson, L., von Knorring, L., Oreland, L., Perris, H., Ross, S. B.: Enzymes related to biogenic amines metabolism and personality characteristics in depressed patients. Acta Psychiat. Scand. (in press, 1980)Google Scholar
  26. Rando, R. R.: Chemistry and enzymology of kcat inhibitors. Science 185, 320–324 (1974)Google Scholar
  27. Schooler, C., Zahn, T. P., Murphy, D. L., Buchsbaum, M. S.: Psychological correlates of monoamine oxidase activity in normals. J. Nerv. Ment. Dis. 166, 177–186 (1978)Google Scholar
  28. Solatunturi, E., Paasonen, M. K.: Intracellular distribution of monoamine oxidase, 5-hydroxytryptamine and histamine in blood platelets of rabbit. Ann. Med. Exp. Biol. Fenn. 44, 427–430 (1966)Google Scholar
  29. Stillman, R. C., Wyatt, R. J., Murphy, D. L., Rauscher, F. P.: Low platelet monoamine oxidase activity and chronic marijuana use. Life Sci. 23, 1577–1582 (1978)Google Scholar
  30. Sullivan, J. L., Stanfield, C. N., Maltbie, A. A., Hammett, E., Cavenar, J. O.: Stability of low blood platelet monoamine oxidase activity in human alcoholics. Biol. Psychiat. 13, 391–397 (1978)Google Scholar
  31. Tipton, K. F.: Some properties of monoamine oxidase. Adv. Biochem. Psychopharmacol. 5, 11–24 (1972)Google Scholar
  32. Wiberg, Å.: Mitochondrial monoamine oxidase. Studies on its activity in some psychiatric diseases. Umeå University Medical Dissertations, New Series No. 41 (1978)Google Scholar
  33. Wiberg, Å.: Increase in platelet monoamine oxidase activity during controlled abstinence after alcohol abuse. Med. Biol. 57, 133–134 (1979)Google Scholar
  34. Wiberg, Å., Gottfries, C.-G., Oreland, L.: Low platelet monoamine oxidase activity in human alcoholics. Med. Biol. 55, 181–186 (1977)Google Scholar
  35. Winter, H., Herschel, M., Propping, P., Friedl, W., Vogel, F.: A twin study on three enzymes (DBH, COMT, MAO) of catecholamine metabolism. Correlations with MMPI. Psychopharmacology 57, 63–69 (1978)Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • Christopher J. Fowler
    • 1
  • Åsa Wiberg
    • 1
  1. 1.Department of PharmacologyUniversity of UmeåUmeåSweden

Personalised recommendations